“Despite Moderna’s (pharmaceutical company created by the Bill Gates Foundation) cheery press release this morning (20 May 2020), the clinical trial results for its groundbreaking COVID vaccine could not be much worse.
Robert F. Kennedy Jr.
Moderna’s “Clinical Trial Results for Its Groundbreaking COVID Vaccine Could Not Be Much Worse”
… The vaccine, developed and championed by Anthony Fauci and financed by Bill Gates, used an experimental mRNA technology that the two men hoped would allow rapid deployment to meet President Trump’s ambitions “warp speed” timeline.
Dr. Fauci was so confident of his shot’s safety that he waved ferret and primate studies (Moderna suspiciously reported no health data from its mouse studies).
That appears to have been a mistake. Three of the 15 human guinea pigs in the high dose cohort (250 mcg) suffered a “serious adverse event” within 43 days of receiving Moderna’s jab.
Moderna did not release its clinical trial study or raw data, but its press release, which was freighted with inconsistencies, acknowledged that three volunteers developed Grade 3 systemic events defined by the FDA as “Preventing daily activity and requiring medical intervention“.
Moderna allowed only exceptionally healthy volunteers to participate in the study.
A vaccine with those reaction rates could cause grave injuries in 1.5 billion humans if administered to “every person on earth”.
That is the threshold that Gates has established for ending the global lockdown.
Moderna did not explain why it reported positive antibody tests for only eight participants.
These outcomes are particularly disappointing because the most hazardous hurdle for the inoculation is still ahead; challenging participants with wild COVID infection.
Past attempts at developing COVID vaccines have always faltered at this stage as both humans and animals achieved robust antibody response then sickened and died when exposed to the wild virus.
Moderna’s press announcement heralded “Positive Interim Phase 1 findings”.
I have forwarded that claim to my colleagues in securities law; FTC rules restrict the amount of lipstick public companies may slather on bad donkeys.”
Buyer Beware: Covid-19 Vaccine Maker Moderna is Valued in The Stratosphere
by Chuck Jones, Forbes Senior Contributor
Getty
Moderna is front and center in the race to develop a vaccine for Covid-19. In a press release on Monday it stated, “With today’s positive interim Phase 1 data and the positive data in the mouse challenge model, the Moderna team continues to focus on moving as fast as safely possible to start our pivotal Phase 3 study in July and, if successful, file a BLA (Biologics License Application).”
The company has also been cited by Dr. Anthony Fauci who expressed “cautious optimism” Friday about the initial results from a coronavirus vaccine trial — which were widely celebrated this week — and said it remains “conceivable” that a vaccine for the deadly pathogen could be available by the end of the year per an NPR report.
Moderna has not sold any products to generate revenue. It has relied upon collaboration revenue from other companies and grants to fund its research. These are perfectly fine ways to generate revenue, but at some point in time the company needs to successfully develop products that can be sold. The company has 23 mRNA development candidates in its portfolio with 13 in clinical studies.